Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jul 2018 | From External Experts

FGF21 gene therapy as treatment for obesity and insulin resistance

Jimenez, V., et al EMBO Molecular Medicine

Jun 2018 | FROM EXTERNAL EXPERTS

Recent advances in understanding and managing non-alcoholic fatty liver disease

Albhaisa, S., Sanyal A. F1000 Research

Feb 2018 | From External Experts

LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

Le, C.T., et al PLoS One

Jan 2018 | From External Experts

Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling

Lee, S., et al Nature

Jan 2018 | FROM EXTERNAL EXPERTS

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Estes, C. et al. Hepatology

May 2017 | FROM EXTERNAL EXPERTS

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys

Stanislaus, S. et al. Endocrinology

Apr 2017 | FROM EXTERNAL EXPERTS

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

Li, X. et al. Journal of Bone and Mineral Research

Jan 2017 | From External Experts

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

Dulai, P et al Hepatology

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline